"One big pharma is particuarly interested in buying out the company, but there is also a biotech company with money who may be interested in partnering with the company to develop their OXIGON® drug candidate," said one source who spoke off the record, but is very familiar with the new developments.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.